Specify a stock or a cryptocurrency in the search bar to get a summary
Catalyst Biosciences Inc
CBIOCatalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California. Address: 611 Gateway Boulevard, South San Francisco, CA, United States, 94080
Analytics
WallStreet Target Price
16 USDP/E ratio
–Dividend Yield
792.92 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CBIO
Dividend Analytics CBIO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CBIO
Stock Valuation CBIO
Financials CBIO
Results | 2019 | Dynamics |